glucagon like peptide 1 glp 1 receptor agonist medications PDB-101: Molecule of the Month: GLP-1 Agonists Patients without diabetes who switched

GLP-1 receptors have been identified within myocardial tissue and autonomic centres [21,22,23], with murine studies demonstrating effects on heart rate, endothelial function and regulation of the autonomic nervous system [24,25,26]

Delayed gastric emptying, gastroparesis-like symptoms, intestinal obstruction, biliary disease, and pancreatic safety concerns were variably reported, with heterogeneous and sometimes conflicting evidence across studies

Common side effects tend to be mild and go away the longer you are on the medication

Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity